Tanespimycin in Treating Patients With Stage III-IV Melanoma

Status Terminated

Clinical Trial Summary

This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. Determine if treatment with 17-AAG results in measurable anti-tumor effects and calculate the proportion of clinical responses.

II. Test the hypothesis that treatment with 17-AAG can disrupt the MAPK pathway by depleting intra-tumor stores of RAF kinases and/or downstream proteins such as phospho-ERK, CDK4 and cyclin D1.

III. Determine if either of these effects correlates with the presence of mutated BRAF within the melanoma tumor.

OUTLINE: This is a multicenter study. Patients are stratified according to presence of BRAF mutation in tumor (yes vs no).

Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00087386
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Withdrawn	`NCT01216787` - RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery	Phase 2
Active, not recruiting	`NCT01026324` - Dinaciclib in Treating Patients With Stage III-IV Melanoma	Phase 1/Phase 2
Completed	`NCT01010984` - LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma	N/A
Completed	`NCT00553306` - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma	Phase 1/Phase 2
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Completed	`NCT00019448` - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Active, not recruiting	`NCT03200847` - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	Phase 1/Phase 2
Active, not recruiting	`NCT03235245` - Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib	Phase 2
Terminated	`NCT01875653` - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma	Phase 3
Completed	`NCT01748747` - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery	Early Phase 1
Terminated	`NCT01316692` - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma	Phase 2
Active, not recruiting	`NCT01120275` - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma	Phase 2
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Terminated	`NCT01026051` - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma	Phase 2
Terminated	`NCT01166126` - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV	Phase 2
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Completed	`NCT00288041` - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00074308` - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers	Phase 1/Phase 2
Completed	`NCT00072163` - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma	Phase 2